Journal article icon

Journal article

RDP58 is a novel and potentially effective oral therapy for ulcerative colitis.

Abstract:

BACKGROUND: RDP58 is a novel anti-inflammatory d-amino acid decapeptide that inhibits synthesis of proinflammatory cytokines by disrupting cell signaling at the pre-MAPK MyD88-IRAK-TRAF6 protein complex. We therefore evaluated its efficacy and safety in parallel multicenter, double-blind, randomized concept studies in ulcerative colitis (UC). METHODS: In the first trial, 34 patients with mild to moderate active UC were randomized (1:2) to placebo (n = 13) or RDP58 100 mg (n = 21). In the sec...

Expand abstract
Publication status:
Published

Actions


Access Document


Authors


More by this author
Institution:
University of Oxford
Department:
Oxford, MSD, Clinical Medicine, Experimental Medicine Division,
Lazarov, M More by this author
Expand authors...
Journal:
Inflammatory bowel diseases
Volume:
11
Issue:
8
Pages:
713-719
Publication date:
2005-08-05
DOI:
EISSN:
1536-4844
ISSN:
1078-0998
URN:
uuid:c8eaca4b-0bd3-498c-85bb-dcd26ce215a7
Source identifiers:
111485
Local pid:
pubs:111485

Terms of use


Metrics



If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP